CClinicalTrials.gg
RecruitingNCT07322705Updated Aug 13, 2026

Can Perineal Post-Free Traction in Hip Arthroscopy Effectively Reduce Perineal Complications?

An interventional study of Perineal Post-Free Traction and Perineal Post Traction in Femoroacetabular Impingement Syndrome, sponsored by ChunBao Li. Recruiting at 10 sites in China. Open to participants aged 15 Years to 60 Years. Per ClinicalTrials.gov, last updated 2026-08-13.

Sponsored by ChunBao Li · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
270
Allocation
Randomized
Ages
15 Years to 60 Years
Sex
All
01

Study summary

The goal of this clinical trial is to analyze the impact of perineal post-free traction versus traditional perineal post traction on perineal complications in hip arthroscopy. The main question it aims to answer is:

  • Can Perineal Post-Free Traction in Hip Arthroscopy Effectively Reduce Perineal Complications? Researchers will compare the perineal-post-free traction group with the conventional perineal-post traction group to see if the former decreases perineal complications and improves efficiency without compromising surgical outcomes.

Participants will:

  • Undergo either perineal-post-free or standard perineal-post traction during hip arthroscopy
  • Complete nerve-injury checks on day 1 and at discharge, and hip-function questionnaires (VAS, mHHS, IHOT-12, HOS) at 3 months
  • Allow collection of operating times, hospital stay, and direct medical costs for economic analysis
02

Conditions studied

  • Femoroacetabular Impingement Syndrome
03

Who can participate

Ages eligible
15 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Aged 15 to 60 years;
  • Met the diagnostic criteria of femoroacetabular impingement syndrome (FAI) and indicated for hip arthroscopy based on patient history, symptoms, signs, physical examination, imaging (pelvic anteroposterior view, frog-leg view, CT 3D reconstruction, MRI), and diagnostic injections;
  • Able to read and sign the informed consent form.

Exclusion criteria

Exclusion Criteria:

  • History of high-energy hip trauma, previous ipsilateral or contralateral hip surgery, avascular necrosis of the femoral head, slipped capital femoral epiphysis, Perthes disease, severe osteoporosis, tumors, acetabular stress fractures, or proliferative or immune hip diseases;
  • Diseases causing groin numbness, foot numbness, sexual dysfunction, urinary dysfunction, skin injuries, perineal injuries, nerve injuries, radicular pain, inner or outer thigh numbness;
  • Abnormal heart, lung, liver, kidney function, severe coagulation disorders, poorly controlled diabetes, judged by the researcher to have an infection risk;
  • Consciousness disorders, psychiatric disorders, or neuromuscular dysfunction affecting lower limb function;
  • Active infection foci (systemic or local infectious lesions);
  • Pregnancy, lactation, or planned pregnancy during the clinical study period;
  • Participation in another clinical trial within the past 3 months;
  • Patients deemed unsuitable for the clinical trial by the researcher for other reasons.
04

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
270 participants (estimated)

Study arms

  • Experimental
    Perineal Post-Free Traction

    Procedure: Perineal Post-Free Traction

  • Active comparator
    Perineal Post Traction

    Procedure: Perineal Post Traction

Interventions

  • ProcedurePerineal Post-Free Traction

    Traction achieved with a thoraco-abdominal belt and contralateral groin strap; operating table tilted 10-15° Trendelenburg under fluoroscopy to 8-10 mm joint space. No perineal post is used, eliminating direct perineal pressure.

  • ProcedurePerineal Post Traction

    Standard traction table with padded perineal post placed against the groin providing counter-traction; affected limb distracted under fluoroscopy to 8-10 mm joint space while contralateral limb is abducted.

05

What researchers measure

Primary outcomes

  1. The incidence of perineal nerve injury

    The incidence of perineal nerve injury included: perineal numbness, pain, soft tissue injury, sexual function and urinary dysfunction.

    Time frame: The first day after surgery

Secondary outcomes

  1. The incidence of pain, numbness, soft tissue injury in other places

    Lower limb ankle numbness and soft tissue injury; the contralateral groin pain, numbness and soft tissue injury; chest pain, numbness, soft tissue injury with fixed place

    Time frame: The first day after surgery

  2. Patients at discharge perineum area incidence of nerve injury

    Patients at discharge perineum area incidence of nerve injury include: perineum area numbness, pain, soft tissue injuries, sexual and urinary dysfunction.

    Time frame: 7 days after surgery

  3. Intraoperative traction time

    Intraoperative traction time

    Time frame: During surgery (intraoperatively)

  4. Preoperative preparation time

    Preoperative preparation time

    Time frame: Immediately before surgery (preoperatively)

  5. Operating time

    Operating time

    Time frame: During surgery (intraoperatively)

  6. The average length of hospital stay after surgery

    The average length of hospital stay after surgery

    Time frame: 6 weeks after surgery

  7. Postoperative joint function assessment

    Visual Analog Scale (VAS) (range 0-10; higher scores indicate worse outcomes).

    Time frame: 3 months after surgery

  8. Postoperative joint function assessment

    Modified Harris Hip Score (mHHS) (range 0-100; higher scores indicate better outcomes).

    Time frame: 3 months after surgery

  9. Postoperative joint function assessment

    Hip Outcome Score (HOS) (range 0%-100%; higher scores indicate better outcomes).

    Time frame: 3 months after surgery

  10. Postoperative joint function assessment

    International Hip Outcome Tool 12-Item Questionnaire (iHOT-12), range 0-100, higher scores mean better hip function

    Time frame: 3 months after surgery

  11. Economic Evaluation - Pain Intensity

    This study will conduct an economic evaluation from a healthcare sector and societal perspective. Pain intensity is assessed using the Visual Analog Scale (VAS), a unidimensional measure reported as scores on a 0-100 mm scale. Effectiveness analysis will incorporate this clinical outcome. Safety will be evaluated by monitoring the incidence of adverse events within 3 months postoperatively.

    Time frame: 14 days after surgery

  12. Economic Evaluation - Hip Function

    This study will conduct an economic evaluation from a healthcare sector and societal perspective. Hip function is assessed using the modified Harris Hip Score (mHHS), a measure specifically for hip dysfunction and related symptoms, reported as scores on a 0-100 scale. Effectiveness analysis will incorporate this clinical outcome. Safety will be evaluated by monitoring the incidence of adverse events within 3 months postoperatively.

    Time frame: 14 days after surgery

  13. Mean Total Healthcare Cost per Patient within 14 Days Postoperatively

    This is the cost input measure for the economic evaluation, adopting a healthcare system perspective. All direct medical costs related to the surgery and subsequent care from the day of surgery until 14 days postoperatively will be collected via the Hospital Information System. Costs include fees for surgery, anesthesia, medical supplies, hospitalization, medication, imaging and laboratory tests, and additional costs for managing complications. The mean total cost per patient (in Chinese Yuan, CNY) will be calculated separately for the "conventional perineal-post traction group" and the "perineal-post-free traction group".

    Time frame: Data collection period: From randomization until 14 days postoperatively.

06

Study locations

10 of 10 sites recruiting
  • Chinese PLA General Hospital
    Beijing, Beijing Municipality 100143, China
    Recruiting
  • Shenzhen Second People's Hospital
    Shenzhen, Guangdong 518035, China
    Recruiting
  • Luoyang Orthopedic Traumatological Hospital of Henan
    Luoyang, Henan 471002, China
    Recruiting
  • The Affiliated Drum Tower Hospital, Medical School of Nanjing University
    Nanjing, Jiangsu 210008, China
    Recruiting
  • The Second Affiliated Hospital of Air Force Medical University (AFMU)
    Xi'an, Shaanxi 710038, China
    Recruiting
  • The Second Affiliated Hospital of Shandong First Medical University
    Tai’an, Shandong 271000, China
    Recruiting
  • Shanghai General Hospital
    Shanghai, Shanghai Municipality 200080, China
    Recruiting
  • West China Hospital, Sichuan University
    Chengdu, Sichuan 610041, China
    Recruiting
  • The First Affiliated Hospital of Kunming Medical University
    Kunming, Yunnan 650032, China
    Recruiting
  • Zhejiang Provincial Hospital of Chinese Medicine
    Hangzhou, Zhejiang 310006, China
    Recruiting
07

References and documents

Individual participant data

Plan to share: No — Individual participant data (IPD) will not be shared with external independent researchers. The original informed consent only permits internal study team, institutional ethics committee and regulatory authorities to access coded data for trial quality control, without explicit participant consent for sharing de-identified IPD for external secondary research. Full trial protocol, statistical analysis plan and analytic codes are available to eligible researchers for result replication upon reasonable request.

No publications or documents are linked to this record.

08

Registry details

Key details

Study ID
NCT07322705
Lead sponsor
ChunBao Li
Responsible party
ChunBao Li (Director of the Department of Sports Medicine, Chinese PLA General Hospital) — Sponsor-investigator
First posted
Jan 7, 2026
Start date
Mar 30, 2026
Primary completion
Sep 30, 2026 (estimated)
Completion
Dec 30, 2026 (estimated)
Last update
Aug 13, 2026

Study contacts

chunbao li, MD
Contact
lichunbao301@163.com
+86-010-66938206
long wang, MD
Contact
longwangbj@163.com
+86-010-66848954
chunbao li, MD
principal investigator · Chinese PLA General Hospital

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion